Mycobacterium tuberculosis Vaccines
Creative Biolabs is a leading global research institute which provides a series of vaccine development solutions for worldwide customers. With our proven competencies and regulatory expertise, we are therefore confident in offering the best services for Mycobacterium tuberculosis vaccines development and guarantee the finest results for our customers all over the world.
Mycobacterium tuberculosis, a member of Mycobacteriaceae family, is a significant cause of a wide variety of human diseases such as tuberculosis. It is also associated with high mortality and infections in mammals. This bacterium is mainly spread through droplets containing tuberculosis from the respiratory tract of infected patients to uninfected individuals. The clinical symptoms include a chronic cough with blood-containing sputum, fever, and weight loss. More than nine species have been identified in this bacterium, including M. tuberculosis sensu stricto, M. africanum, M. canetti, M. bovis, M. caprae, M. microti, M. pinnipedii, M. mungi, and M. orygis. In this condition, the BCG vaccine has been developed for diseases prevention, and the data show that this vaccine is safe and efficient for vaccination against tuberculosis.
Fig.1 The Infection Mechanism of Mycobacterium tuberculosis. (Madhukar.P, et al., 2016)
The BCG Vaccines
The Bacillus Calmette-Guérin (BCG) vaccine is the only available vaccine for TB infections. It is a live attenuated vaccine widely used in tuberculosis prevention. BCG is usually derived from a weaken strain (Mycobacterium bovis) of TB bacteria. Research suggest that children aged under 5 years are at higher risk of Mycobacterium tuberculosis infection. The BCG vaccine can provide effective protection for infants and young children with minor side effects. However, the deletion variants of BCG can cause the lacking of the encoding regions for highly immunogenic antigens, such as RD1 and RD2 region. Meanwhile, the study shows that the efficacy is variable in adults, ranging from 0% to 80%. BCG cannot provide effective protection against M. tuberculosis infection in adults. Because of the limitations of the existing vaccines, other types of M. tuberculosis vaccines are still at various stages of developments. The studies suggest a new VPM1002 is the most advanced BCG strain under development and has been engineered in several studies. These potential vaccines should play a significant role in M. tuberculosis prevention in the near future.
The Candidates for M. tuberculosis Vaccines
Compared with BCG, M. tuberculosis has the compete genes for encoding the immunogenic antigens. For this reason, live-attenuated M. tuberculosis strains are regarded as potential candidates for the development of a more effective vaccine. There are several strains that have been proven to have the ability to provide enough protective immunity similar to BCG, including a secA2 deleted strain, a phoP mutant strain, as well as a new MTBVAC01 strain. Meanwhile, a number of antigens of M. tuberculosis have also been found, which can be used to improve the protective potential, such as Ag85B, RD1, MPT64. Among these antigens, the results indicate that the high expression of Ag85B and MPT64 lead to a superior protective activity than parental BCG. In addition, research also reveal that the ESX-1 secretion system plays an important role in identifying candidate antigens. Secreted proteins as MPT64 and MPT83 and other secreted or cell-bound antigens such as Ag85A/B, HSP65, PPE18 can provide a full range of M. tuberculosis candidate antigens.
Our Services for Mycobacterium tuberculosis Vaccines
Our platform is strictly in accordance with GCP's requirements, and the temperature, humidity and experimental facilities in the laboratory are all world advanced. We provide a comprehensive vaccine development for Mycobacterium tuberculosis. Our services are designed to provide a cost-efficient and efficient outsourcing solution.
- Well-established vaccine development system
- Rapid results, flexible development service
- Multiple robust technologies
Creative Biolabs is a research-driven and customer-focused company, which has focused on the vaccine development services for years. If you are interested in our services, please contact us for more details.
Reference
- Madhukar.P, et al. (2016). “Tuberculosis.” Nature Reviews Disease Primers.16, 76.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
